IceCure Medical Ltd (NASDAQ:ICCM) Short Interest Down 22.7% in February

IceCure Medical Ltd (NASDAQ:ICCM) was the recipient of a large drop in short interest in February. As of February 28th, there was short interest totalling 598,100 shares, a drop of 22.7% from the February 13th total of 773,300 shares. Currently, 2.1% of the shares of the stock are short sold. Based on an average trading volume of 385,300 shares, the days-to-cover ratio is currently 1.6 days.

Institutional Investors Weigh In On IceCure Medical

An institutional investor recently raised its position in IceCure Medical stock. Geode Capital Management LLC boosted its stake in IceCure Medical Ltd (NASDAQ:ICCM) by 58.3% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 40,453 shares of the company’s stock after purchasing an additional 14,893 shares during the quarter. Geode Capital Management LLC owned about 0.07% of IceCure Medical worth $44,000 as of its most recent filing with the SEC. 0.62% of the stock is currently owned by institutional investors and hedge funds.

IceCure Medical Trading Down 2.7 %

Shares of NASDAQ ICCM traded down $0.04 during midday trading on Wednesday, reaching $1.43. 34,037 shares of the stock were exchanged, compared to its average volume of 510,711. The company has a market capitalization of $79.42 million, a P/E ratio of -4.94 and a beta of 0.37. IceCure Medical has a 52-week low of $0.48 and a 52-week high of $1.66. The company has a current ratio of 2.67, a quick ratio of 2.27 and a debt-to-equity ratio of 0.02. The stock has a 50 day moving average price of $1.32 and a 200-day moving average price of $0.96.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and set a $2.50 target price on shares of IceCure Medical in a report on Wednesday, November 27th.

About IceCure Medical

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.